New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
09:11 EDTBKW, ADXS, QIHU, X, TRP, INSY, RGDO, RHHBY, ITMN, THI, MRKOn The Fly: Pre-market Movers
HIGHER: Burger King (BKW), up 13% after confirming talks regarding a potential strategic transaction with Tim Hortons (THI). Shares of the Canadian donut shop operator trading in New York are also up 17%... InterMune (ITMN), up 36% after Roche (RHHBY) agreed to acquire the company for $74.00 per share... Advaxis (ADXS), up 4% after entering clinical trial collaboration agreement with Merck (MRK)... Insys Therapeutics (INSY), up 5.5% after receiving FDA orphan drug designation for CBD... TransCanada (TRP), up 2.2% after Barron's says the company could climb 35%... U.S. Steel (X), up 3.7% after upgraded at Credit Suisse. LOWER: Regado (RGDO), down 52% after the company terminated enrollment in its REGULATE-PCI Phase 3 trial... Qihoo 360 (QIHU), down 5% after reporting Q2 earnings, Q3 outlook.
News For BKW;THI;ITMN;RHHBY;RGDO;INSY;TRP;X;QIHU;ADXS;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 17, 2014
12:08 EDTXSteel stocks rally as U.S. Steel, Nucor provide improved outlooks
Subscribe for More Information
11:52 EDTXStocks with call strike movement; X GILD
Subscribe for More Information
11:00 EDTRHHBYRoche CEO rules out megadeals, focused on bolt-on acquisitions, WSJ says
Roche CEO Severin Schwan said the company won't change its acquisition strategy following the recent deals made or abandoned in the pharmaceutical sector, reports the Wall Street Journal. In an interview with WSJ, Shwan said, "We have been very consistent in our approach to M&A." Regarding transformational deal-making, he said, "We have no intention to do that, whatever happens in the industry." Reference Link
10:12 EDTXU.S. Steel rallies sharply following Q3 update, levels to watch
Subscribe for More Information
09:36 EDTXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL WFM X YHOO TSLA TWTR RAX SHLD SPLS
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
09:10 EDTXOn The Fly: Pre-market Movers
Subscribe for More Information
08:33 EDTXU.S. Steel price target raised to $58 from $47 at Goldman
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
08:19 EDTXU.S. Steel remains top pick in steel space, says Cowen
Subscribe for More Information
07:43 EDTRHHBYBofA/Merrill to hold a conference
Subscribe for More Information
06:18 EDTXU.S. Steel volatility expected to move after updating Q3 outlook
Subscribe for More Information
September 16, 2014
18:30 EDTXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Apogee Enterprises (APOG), up 5.6% after reporting second quarter results and raising fiscal 2015 guidance. ALSO HIGHER: InspireMD (NSPR), up 18.5% after reporting positive trial results for CGuard... Boeing (BA), up marginally after NASA awarded the company with a $4.2B contract for commercial spaceflight to the International Space Station... U.S. Steel (X), up 7.9%% after updating third quarter outlook. DOWN AFTER EARNINGS: Adobe (ADBE), down 4.5% following third quarter results. ALSO LOWER: Rackspace Hosting (RAX), down 16.7% after ending strategic review and deciding to stay independent... Sunoco Logistics Partners (SXL), down 3.9% after filing to sell 7.7M shares of common stock... Aratana Therapeutics (PETX), down 7.8% after filing to sell common stock.
18:20 EDTXU.S. Steel up nearly 8% in after hours following Q3 update, strategic actions
Subscribe for More Information
18:17 EDTXU.S. Steel sees Q3 ex-items EPS 'significantly higher' than current consensus
Consensus for Q3 EPS is 89c.
18:14 EDTXU.S. Steel updates Q3 outlook, sees significant improvement in operating income
Subscribe for More Information
18:09 EDTXU.S. Steel announces decision to not proceed with Keewatin, Gary Works expansion
Subscribe for More Information
13:19 EDTTHIMcDonald's Canada to offer coffee in grocery stores, Reuters says
McDonald's (MCD) is poised to start offering its McCafe ground coffee throughout Canadian grocery stores this month in an effort to gain more customers in a country whose java market has been lead by competitors such as Tim Hortons (THI) and Starbucks (SBUX), according to Reuters, citing comments from McDonald's Canada CEO John Betts. Reference Link
07:31 EDTRHHBY, MRKEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:25 EDTMRKMerck price target raised to $72 from $62 at SunTrust
After meeting with Merck's CEO and head of clinical development, SunTrust increased its price target on the company as the firm thinks that it is ideally positioned across five of the fastest growing therapeutic classes. The firm believes that the company's EPS growth rates from 2015-2020 will be three percentage points above Street estimates, while it has a first-mover advantage in oncology. It keeps a Buy rating on the shares.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use